Market Closed -
Japan Exchange
11:30:00 22/05/2024 am IST
|
5-day change
|
1st Jan Change
|
234
JPY
|
-2.09%
|
|
-3.70%
|
+24.47%
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,431
|
-
|
-
|
Enterprise Value (EV)
1 |
9,431
|
9,431
|
9,431
|
P/E ratio
|
-107
x
|
-7.31
x
|
-7.31
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.5
x
|
-
|
-
|
EV / Revenue
|
13.5
x
|
-
|
-
|
EV / EBITDA
|
-9.93
x
|
-7.46
x
|
-7.31
x
|
EV / FCF
|
-111
x
|
-10.5
x
|
-7.25
x
|
FCF Yield
|
-0.9%
|
-9.54%
|
-13.8%
|
Price to Book
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,304
|
-
|
-
|
Reference price
2 |
234.0
|
234.0
|
234.0
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net sales
1 |
700
|
-
|
-
|
EBITDA
1 |
-950
|
-1,265
|
-1,290
|
EBIT
1 |
-85.1
|
-1,275
|
-1,300
|
Operating Margin
|
-12.16%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-79
|
-1,275
|
-1,300
|
Net income
1 |
-80
|
-1,275
|
-1,300
|
Net margin
|
-11.43%
|
-
|
-
|
EPS
2 |
-2.190
|
-32.00
|
-32.00
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
FCF margin
|
-12.13%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024 Q4
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
1 |
13.23
|
Dividend per Share
|
-
|
Announcement Date
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
Capex
1 |
10
|
10
|
10
|
Capex / Sales
|
1.43%
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Average target price
760
JPY Spread / Average Target +224.79% Consensus |
1st Jan change
|
Capi.
|
---|
| +24.47% | 61.7M | | +59.00% | 55.07B | | -2.04% | 41.79B | | +44.36% | 40.22B | | -8.29% | 28.17B | | +11.82% | 26.28B | | -21.08% | 18.93B | | +6.32% | 13.03B | | +28.21% | 12.26B | | +25.46% | 12.21B |
Other Biotechnology & Medical Research
|